Moxifloxacin - Bromfenac Sterile Ophthalmic Solution 0.5% / 0.075%, 5mL bottle, Imprimis NJOF, LLC. 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852 (844)-446-6979, NDC: 71384-311-05.

Subpotent Drug; sub-potent Bromfenac levels, below the 90.0-110.0% specification range.

Recall #: D-1094-2023
Affected scope: 2,683 bottles
Initiated: August 10, 2023

Compiled from official public sources by the publisher. · Updated September 2026

Imprimis Njof, LLC recalled Moxifloxacin - Bromfenac Sterile Ophthalmic Solution 0.5% / 0.075%, 5mL bottle, Imprimis … - a low-severity action.

Moxifloxacin - Bromfenac Sterile Ophthalmic Solution 0.5% / 0.075%, 5mL bottle, Imprimis … was recalled by Imprimis Njof, LLC in August 30, 2023. Reason: Subpotent Drug; sub-potent Bromfenac levels, below the 90.0-110.0% specification range.. Check the official notice for the remedy. Verify recall #D-1094-2023 with the FDA Drug before acting.

The recall

Imprimis Njof, LLC issued this low-severity FDA Drug recall-Subpotent Drug; sub-potent Bromfenac levels, below the 90.0-110.0% specification range..

Low
severity level: Class III
classification: August 30, 2023
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-1094-2023 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This recall's affected scope, documented in the Recall Profile below, stays within a single-region or limited-distribution footprint. Distribution scope (see Distribution below) directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 6 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Where this agency-classified recall sits among FDA Class I/II/III notices

Of 88,244 recalls with an agency hazard classification, 19,068 are high severity, 64,652 moderate, and 4,524 low. A further 16,179 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified low severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Product description

Moxifloxacin - Bromfenac Sterile Ophthalmic Solution 0.5% / 0.075%, 5mL bottle, Imprimis NJOF, LLC. 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852 (844)-446-6979, NDC: 71384-311-05.

Reason for recall

Subpotent Drug; sub-potent Bromfenac levels, below the 90.0-110.0% specification range.

Recall Profile

Structured summary of the FDA Drug recall record
Attribute	Value
Agency	U.S. Food and Drug Administration
Severity class	Low (Class III)
Status	Terminated
Recall number	D-1094-2023
Date reported	August 30, 2023
Date initiated	August 10, 2023
Recalling firm	Imprimis Njof, LLC
Firm location	Ledgewood, NJ
Affected scope	2,683 bottles
Distribution	Nationwide in the US

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

Check the recall number (D-1094-2023) and product description against the item you own. Search the archive
Confirm the current status with FDA Drug before acting, recall details can be updated.
Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled? ▼

Moxifloxacin - Bromfenac Sterile Ophthalmic Solution 0.5% / 0.075%, 5mL bottle, Imprimis NJOF, LLC. 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852 (844)-446-6979, NDC: 71384-311-05.. Recalled by Imprimis Njof, LLC. Units affected: 2,683 bottles.

Why was this product recalled? ▼

Subpotent Drug; sub-potent Bromfenac levels, below the 90.0-110.0% specification range.

Which agency issued this recall? ▼

This recall was issued by the FDA Drug on August 30, 2023. Severity: Low. Recall number: D-1094-2023.

Where was the recalled product distributed? ▼

Distribution: Nationwide in the US.

Should I stop using a recalled medication or medical device? ▼

Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nationwide recalls with similar severity or category timing

Drug and device notices outside this firm and state, matched by severity timing and product category.

Similar severity · nearest report date

Same archive severity grade (Low), closest by report date among other firms and states.

Bendamustine HCl Injection, 100mg/4mL (25… 2023-08-30 Clindamycin Phosphate Topical Solution US… 2023-09-06 Sabril (vigabatrin) for Oral Solution, 50… 2023-09-06 Dilettante Mocha Cafe brand Dark Ephemere… 2023-08-23

Similar Drugs & Medications · nearest report date

Same product category, closest by report date among other firms and states (deduped against the severity set).

Blis-To-Sol Liquid (Tolnaftate), 1%, pack… 2023-08-30 YAGER'S LINIMENT (Camphor and Turpentine … 2023-08-30 ALCOLADO RELAMPAGO (Menthol and Camphor),… 2023-08-30 Unguentine Ointment, (Camphor 3.0%, Pheno… 2023-08-30

Compare this recall with Kian Pee Wan Capsules, 30-count bottles → · All Drugs & Medications recalls

This recall: FDA Drug, reported August 30, 2023. Severity classes follow each agency's own taxonomy; related-recall context is computed across the full archive.

Methodology · Corrections · Archive as of August 2026